XML 44 R33.htm IDEA: XBRL DOCUMENT v3.21.2
Summary of Significant Accounting Policies - Additional Information (Detail)
3 Months Ended 9 Months Ended 12 Months Ended
Sep. 30, 2021
USD ($)
Sep. 30, 2020
USD ($)
Sep. 30, 2021
USD ($)
Segment
Sep. 30, 2020
USD ($)
Dec. 31, 2020
USD ($)
Number of operating segments | Segment     1    
Clinical trial cost $ 43,000 $ 882,000 $ 1,123,000 $ 2,127,000  
Research development and clinical trials expenses 400,000 $ 300,000 $ 1,600,000 $ 1,100,000  
Revenue performance obligation description of payment terms     Payment terms for customer orders, including for each of the Company’s primary performance obligations, are typically 30 days for customers in the United States and 30 to 90 days for customers in non-U.S. markets, and such payments do not include payments that are variable, dependent on specified factors or events.    
Contract assets 0   $ 0   $ 0
Performance obligations totaled 800,000   $ 800,000    
Revenue performance obligation description of timing     The Company generally satisfies performance obligations within one year of the contract inception date.    
Minimum [Member]          
Common stock held by non-affiliates 700,000,000.0   $ 700,000,000.0    
Maximum [Member]          
Clinical trial cost $ 100,000        
Customer Concentration Risk | Revenue Benchmark | Significant Customer Benchmark [Member] | Minimum [Member]          
Concentration risk percentage     10.00%    
Customer Concentration Risk | Revenue Benchmark | Customer One [Member]          
Concentration risk percentage 16.00% 12.00% 10.00% 13.00%  
Customer Concentration Risk | Revenue Benchmark | Customer Two [Member]          
Concentration risk percentage 12.00% 14.00%   12.00%  
Customer Concentration Risk | Accounts Receivable | Significant Customer Benchmark [Member] | Minimum [Member]          
Concentration risk percentage     10.00%    
Customer Concentration Risk | Accounts Receivable | Customer One [Member]          
Concentration risk percentage     20.00%   30.00%
Customer Concentration Risk | Accounts Receivable | Customer Two [Member]          
Concentration risk percentage     11.00%